Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.

Abstract : Background:Gemcitabine/Cisplatin (Gem/CDDP) combination has demonstrated a clear survival advantage overgemcitabine alone and has become a new standard in advanced Biliary Tract Carcinoma (aBTC). However,Gemcitabine/Oxaliplatin (GEMOX) combination and Gemcitabine/Carboplatin (Gem/Carb) combination regimenshave shown efficacy in phase II trials and there is no comparative study between different platinum salts.We assessed the efficacy and safety of different platinum-based chemotherapies at first line in aBTC patients. Wealso analysed the second-line chemotherapy.Methods:Sixty-four consecutive patients with aBTC diagnosed between 1998 and 2010 were included for analysis.At first line chemotherapy, 44 patients received one day GEMOX regimen (gemcitabine 1000 mg/m2and oxaliplatin100 mg/m2Day 1, every 2 weeks), and 20 patients received Gem/Carb regimen (gemcitabine at 1000 mg/m2Days1 and 8 with carboplatin delivered according to an area-under-the-curve (AUC) 5 at day 1, every 3 weeks). Atsecond line, a total of 16 patients received a fluoropyrimidine-based chemotherapy.Results:With GEMOX regimen, median progression-free survival (PFS) was 3.7 months (95%CI, 2.4 to 5) and medianoverall survival (OS) was 10.5 months (95%CI, 6.4 to14.7). The main toxicity was peripheral neuropathy (20% grade 2and 7% grade 3). Grade 3/4 haematological toxicities were rare.With Gem/Carb regimen, PFS was 2.5 months (95%CI, 2.1 to 3.7) and OS was 4.8 months (95%CI, 3.7 to 5.8). Themain grade 3/4 toxicities were haematological: anaemia (45%), thrombocytopenia (45%), and neutropenia (40%).At second-line, fluoropyrimidine-based chemotherapy was feasible in only a fourth of the patients. The median OSwas 5.3 months (95%CI, 4.1 to 6.6), and median PFS was 4.0 months (95%CI, 2.6 to 5.5).Conclusions:One day GEMOX regimen has a favourable toxicity profile and could be an alternative to standardGem/CDDP regimen, in particular in unfit patients for CDDP.At second-line, selective patients may benefit from fluoropyrimidine-based chemotherapy.
Type de document :
Article dans une revue
BMC Gastroenterology, BioMed Central, 2013, pp.143
Liste complète des métadonnées

Littérature citée [21 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01096384
Contributeur : Nadia Taibi <>
Soumis le : mercredi 17 décembre 2014 - 13:52:07
Dernière modification le : jeudi 15 février 2018 - 08:48:15
Document(s) archivé(s) le : lundi 23 mars 2015 - 15:11:12

Fichier

1471-230X-14-143.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

  • HAL Id : inserm-01096384, version 1
  • PUBMED : 25117717

Collections

Citation

Frédéric Fiteni, Marine Jary, Franck Monnien, Thierry Nguyen, Eric Beohou, et al.. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.. BMC Gastroenterology, BioMed Central, 2013, pp.143. 〈inserm-01096384〉

Partager

Métriques

Consultations de la notice

171

Téléchargements de fichiers

118